BioCentury on BioBusiness,
Emerging Company Profile
EnBiotix using two mechanisms to increase sensitivity to antibiotics
Related tables, figures and sidebars
EnBiotix: Enhancing antibiotics
Monday, February 11, 2013
Inc. is discovering compounds that make infections more susceptible to
existing antibiotics either by increasing the bacterias' production of reactive
oxygen species, or by activating their metabolic pathways. The company is
aiming for a discovery alliance followed by an A round that will help fund
development of its candidates.
EnBiotix's discovery programs are based on the work of Boston
University's James Collins, whose lab has used systems biology
approaches to study bacterial responses to antibiotics. Collins is a professor
of biomedical engineering at the university, a founding core member of the Wyss
Institute for Biologically Inspired Engineering at Harvard University
and a Howard
Hughes Medical Institute investigator.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]